Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections
| Autor: | L. Eyrolle, Emmanuel Curis, Jean-Claude Nguyen Van, Matthieu Karoubi, Vincent Pestre, L. Gatin, Philippe Anract, Antoine Babinet, Dominique Salmon, Vincent Jullien, Denis Archambeau, Valérie Dumaine, Philippe Morand, Nicolas Pinar |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Microbiology (medical)
Adult Male medicine.medical_specialty Adolescent medicine.drug_class Antibiotics medicine.disease_cause Gastroenterology Minimum inhibitory concentration Young Adult Pharmacotherapy Pharmacokinetics Internal medicine medicine Humans Trough Concentration Drug Interactions Gram-Positive Bacterial Infections Aged Aged 80 and over business.industry Clindamycin Osteomyelitis General Medicine Middle Aged Surgery Anti-Bacterial Agents Infectious Diseases Drug Therapy Combination Female Rifampin business Staphylococcus Rifampicin medicine.drug |
| Zdroj: | Infection. 43(4) |
| ISSN: | 1439-0973 |
| Popis: | Clindamycin, a lincosamide antibiotic with a good penetration into bone, is widely used for treating bone and joint infections by Gram-positive pathogens. To be active against Staphylococcus spp, its concentration at the infection site, C, must be higher than 2× the minimal inhibitory concentration (MIC). The aims of the work were to study the determinants of plasma clindamycin trough concentration, C min, especially the effect of co-treatment with rifampicin, and the consequences on clinical outcome. An observational study was performed, involving patients hospitalized for a bone and joint infection who received clindamycin as part of their antibiotic treatment. Target C min was 1.7 mg/L, to reach the desired bone concentration/MIC >2, assuming a 30 % diffusion into bone and MIC = 2.5 mg/L. Sixty one patients (mean age: 56.8 years, 57.4 % male) were included between 2007 and 2011. 72.1 % underwent a surgery on a foreign material, and 91.1 % were infected by at least a Gram-positive micro-organism. Median C min value was 1.39 mg/L, with 58 % of the values below the threshold value of 1.7 mg/L. Median C min was significantly lower for patients taking rifampicin (0.46 vs 1.52 mg/L, p = 0.034). No patient with rifampicin co-administration reached the target concentration (maximal C min: 0.85 mg/L). After a median follow-up of 17 months (1.5–38 months), 4 patients relapsed, 2 died and 47 (88.7 % of the patients with known outcome) were cured, independently of association with rifampicin. This study shows the high inter-variability of plasma clindamycin concentration and confirms that co-treatment with rifampicin significantly decreases clindamycin trough concentrations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink